Fukuoka Y, Hugli T E
Department of Immunology, Tohoku University, Sendai, Japan.
J Immunol. 1988 May 15;140(10):3496-501.
Guinea pig platelets reportedly contain receptors specific for the anaphylatoxin C3a based on both ligand-binding studies and functional responses. A portion of the human 125I-C3a that binds to guinea pig platelets is competitively displaced by excess unlabeled C3a; however, the majority of ligand uptake was nonspecific. Uptake of 125I-C3a by guinea pig platelets is maximal in 1 min, and stimulation of guinea pig platelets by thrombin, ADP, or the Ca2+ ionophore A23187 showed little influence on binding of the ligand. Scatchard analysis indicated that approximately 1200 binding sites for C3a exist per cell with an estimated Kd of 8 x 10(-10) M. Human C3a des Arg also binds to guinea pig platelets, but Scatchard analysis indicated that no specific binding occurred. Because the ligand-binding studies were complicated by high levels of nonspecific uptake, we attempted to chemically cross-link the C3a molecule to a specific component on the platelet surface. Cross-linkage of 125I-C3a to guinea pig platelets with bis(sulfosuccinimidyl)suberate revealed radioactive complexes at 105,000 and 115,000 m.w. on SDS-PAGE gels by autoradiographic analysis. In the presence of excess unlabeled C3a, complex formation was inhibited. No cross-linkage could be demonstrated between the inactive 125I-C3a des Arg and the putative C3a-R on guinea pig platelets. Human C3a, but not C3a des Arg induces serotonin release and aggregation of the guinea pig platelets. Human C3a was unable to induce either serotonin release or promote aggregation of human platelets. Uptake of human 125I-C3a by human platelets was not saturable, and Scatchard analysis was inconclusive. Attempts to cross-link 125I-C3a to components on the surface of human platelets also failed to reveal a ligand-receptor complex. Therefore, we conclude that guinea pig platelets have specific surface receptors to C3a and that human platelets appear devoid of receptors to the anaphylatoxin.
据报道,基于配体结合研究和功能反应,豚鼠血小板含有对过敏毒素C3a特异的受体。与豚鼠血小板结合的一部分人125I - C3a可被过量未标记的C3a竞争性取代;然而,大部分配体摄取是非特异性的。豚鼠血小板对125I - C3a的摄取在1分钟内达到最大值,凝血酶、ADP或Ca2+离子载体A23187对豚鼠血小板的刺激对配体结合影响很小。Scatchard分析表明,每个细胞存在约1200个C3a结合位点,估计解离常数(Kd)为8×10(-10) M。人C3a去精氨酸(C3a des Arg)也与豚鼠血小板结合,但Scatchard分析表明未发生特异性结合。由于高水平的非特异性摄取使配体结合研究变得复杂,我们尝试将C3a分子化学交联到血小板表面的特定成分上。用双(磺基琥珀酰亚胺基)辛二酸酯将125I - C3a与豚鼠血小板交联,通过放射自显影分析在SDS - PAGE凝胶上显示出分子量为105,000和115,000的放射性复合物。在过量未标记的C3a存在下,复合物形成受到抑制。在无活性的125I - C3a des Arg与豚鼠血小板上假定的C3a受体(C3a - R)之间未证明有交联。人C3a可诱导豚鼠血小板释放5 - 羟色胺并聚集,但C3a des Arg则不能。人C3a不能诱导人血小板释放5 - 羟色胺或促进其聚集。人血小板对人125I - C3a的摄取不饱和,Scatchard分析无定论。将125I - C3a交联到人血小板表面成分的尝试也未能揭示配体 - 受体复合物。因此,我们得出结论,豚鼠血小板具有对C3a的特异性表面受体,而人血小板似乎缺乏对过敏毒素的受体。